Form 4: DaVita Chief Compliance Officer Sells Shares Under Pre-Arranged 10b5-1 Plan

DaVita Inc.'s Chief Compliance Officer, James O. Hearty, sold 2,351 shares of common stock for $150 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• James O. Hearty, Chief Compliance Officer of DaVita Inc., sold 2,351 shares of common stock.
• The sale occurred on July 23, 2025, at a price of $150 per share.
• Following this transaction, James O. Hearty beneficially owns 26,038 shares of DaVita Inc. common stock.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on March 17, 2025.

Sentiment

Score: 5

Explanation: While an insider sale could be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about it being a reaction to adverse internal information, making the sentiment neutral.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, immediate information.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company.

Future Outlook

NA

Industry Context

This filing details a routine insider stock transaction for DaVita Inc., a leading provider of kidney care services. Such transactions are common across all industries for executives managing their personal portfolios, especially when executed under Rule 10b5-1 plans to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale by a Chief Compliance Officer could be viewed as a slight reduction in management's direct equity alignment, though the 10b5-1 plan context lessens its significance.

Key Dates

Recommendation

The filing details a routine, pre-planned insider stock sale by a Chief Compliance Officer. This type of transaction, executed under a Rule 10b5-1 plan, typically does not signal new material information about the company's performance or outlook. Therefore, it provides no basis for a change in investment recommendation, suggesting a 'hold' for existing positions unless other fundamental factors change.

Keywords

DaVita Inc., DVA, Insider Trading, Form 4, Stock Sale, Chief Compliance Officer, Rule 10b5-1, Equity Transaction